Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 14 05 2018
accepted: 21 06 2018
pubmed: 29 6 2018
medline: 11 5 2019
entrez: 29 6 2018
Statut: ppublish

Résumé

Psoriasis is a very prevalent systemic chronic inflammatory disease. Major cardiovascular events are the main cause of mortality in these patients which suggests an association between psoriasis and traditional cardiovascular risk factors. To identify classic cardiovascular risk factors and metabolic syndrome (MS) in patients with psoriasis, their possible association with its severity and compare it with the non-psoriatic population. This is an observational and cross-sectional population study in Lleida (Spain) from a joint hospital/primary care database. The database comprised 398 701 individuals. There were 6868 cases registered as psoriasis (1.7%), and 499 of them (7.3%) were classified as moderate-severe psoriasis. Patients with psoriasis had a higher prevalence of traditional cardiovascular risk factors than non-psoriatic population: diabetes mellitus 2 (13.9% vs 7.4%, OR 2.01), dyslipidaemia (28.8% vs 17.4%, OR 1.92), arterial hypertension (31.2% vs 19.0%, OR 1.93), obesity (33.7% vs 28.1%, OR 1.30), altered fasting basal glycaemia (21.4% vs 15.1%, OR 1.54), low cholesterol HDL (38.1% vs 32.3%, OR 1.29), hypertriglyceridaemia (45.7% vs 35.2%, OR 1.55) and high waist circumference (75.7% vs 72.3%, OR 1.19). MS was more prevalent in psoriatic patients (28.3% vs 15.1%, OR 2.21), and cardiovascular risk factors were similar between psoriasis severity groups. Psoriatic patients had a higher prevalence of ischaemic heart disease (3.3% vs 1.8%, OR 1.87) and vascular cerebral accidents (1.8% vs 1.2%, OR 1.55). A model for MS showed a significant nonlinear relationship with age and sex and significant differences between patients with and without psoriasis. We found statistically significant differences in relation to the prevalence of cardiovascular risk factors, MS and major cardiovascular events in psoriatic patients. However, differences were not seen between psoriasis severity groups. Our work reinforces the need for a multidisciplinary approach and close monitoring of cardiovascular risk factors in these patients to prevent a cardiovascular event.

Sections du résumé

BACKGROUND BACKGROUND
Psoriasis is a very prevalent systemic chronic inflammatory disease. Major cardiovascular events are the main cause of mortality in these patients which suggests an association between psoriasis and traditional cardiovascular risk factors.
OBJECTIVE OBJECTIVE
To identify classic cardiovascular risk factors and metabolic syndrome (MS) in patients with psoriasis, their possible association with its severity and compare it with the non-psoriatic population.
METHODS METHODS
This is an observational and cross-sectional population study in Lleida (Spain) from a joint hospital/primary care database.
RESULTS RESULTS
The database comprised 398 701 individuals. There were 6868 cases registered as psoriasis (1.7%), and 499 of them (7.3%) were classified as moderate-severe psoriasis. Patients with psoriasis had a higher prevalence of traditional cardiovascular risk factors than non-psoriatic population: diabetes mellitus 2 (13.9% vs 7.4%, OR 2.01), dyslipidaemia (28.8% vs 17.4%, OR 1.92), arterial hypertension (31.2% vs 19.0%, OR 1.93), obesity (33.7% vs 28.1%, OR 1.30), altered fasting basal glycaemia (21.4% vs 15.1%, OR 1.54), low cholesterol HDL (38.1% vs 32.3%, OR 1.29), hypertriglyceridaemia (45.7% vs 35.2%, OR 1.55) and high waist circumference (75.7% vs 72.3%, OR 1.19). MS was more prevalent in psoriatic patients (28.3% vs 15.1%, OR 2.21), and cardiovascular risk factors were similar between psoriasis severity groups. Psoriatic patients had a higher prevalence of ischaemic heart disease (3.3% vs 1.8%, OR 1.87) and vascular cerebral accidents (1.8% vs 1.2%, OR 1.55). A model for MS showed a significant nonlinear relationship with age and sex and significant differences between patients with and without psoriasis.
CONCLUSION CONCLUSIONS
We found statistically significant differences in relation to the prevalence of cardiovascular risk factors, MS and major cardiovascular events in psoriatic patients. However, differences were not seen between psoriasis severity groups. Our work reinforces the need for a multidisciplinary approach and close monitoring of cardiovascular risk factors in these patients to prevent a cardiovascular event.

Identifiants

pubmed: 29953676
doi: 10.1111/jdv.15159
doi:

Substances chimiques

Blood Glucose 0
Cholesterol, LDL 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-135

Informations de copyright

© 2018 European Academy of Dermatology and Venereology.

Auteurs

J M Fernández-Armenteros (JM)

Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain.
Dermatology Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.

X Gómez-Arbonés (X)

Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain.
Department of Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain.

M Buti-Soler (M)

Unitat de Suport a la Recerca Lleida, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain.
Institut Català de la Salut, Lleida, Spain.

A Betriu-Bars (A)

Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain.
Nephrology Department, Unitat de Detecció i Tractament de les malalties aterotrombòtiques (UDETMA), Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.

V Sanmartin-Novell (V)

Dermatology Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.

M Ortega-Bravo (M)

CAP Cappont, Lleida, Spain.

M Martínez-Alonso (M)

Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain.

E Garí (E)

Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain.

M Portero-Otín (M)

Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain.

L Santamaria-Babi (L)

Translational Immunology, University of Barcelona, Barcelona, Spain.

J M Casanova-Seuma (JM)

Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain.
Dermatology Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.
Department of Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH